![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 22, 15090-15098, June 2, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B*

1
2



3
From the
Department of Medicine I, University of Erlangen-Nuernberg, 91054 Erlangen, Germany and the
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115
The semisynthetic plant alkaloid halofuginone (HAL) was reported to prevent and partly reverse experimental liver fibrosis. However, its mechanisms of action are poorly understood. We therefore aimed to determine the antifibrotic potential of HAL and to characterize involved signal transduction pathways in hepatic stellate cells (HSCs). Results were compared with its in vivo effects in a rat model of reversal of established liver fibrosis induced by thioacetamide. In vitro HAL inhibited HSC proliferation and migration dose dependently at submicromolar concentrations. HAL (200 nM) up-regulated matrix metalloproteinase (MMP)-3 and MMP-13 expression between 10- and 50-fold, resulting in a 2- to 3-fold increase of interstitial collagenase activity. Procollagen
1(I) and MMP-2 transcript levels were suppressed 2- to 3-fold, whereas expression of other profibrogenic mRNAs remained unaffected. p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor
B(NF
B) pathways were activated by HAL, and specific inhibitors of p38 MAPK and NF
B dose dependently inhibited MMP-13 induction. Treatment with HAL did not affect HSC viability, and observed effects were reversible after its removal. In vivo HAL up-regulated MMP-3 and -13 mRNA expression 1.5- and 2-fold, respectively, in cirrhotic rats, whereas tissue inhibitor of metalloproteinase-1 was suppressed by 50%. In conclusion, submicromolar concentrations of HAL inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF
B. The remarkable induction of MMP-3 and -13 makes HAL a promising agent for antifibrotic combination therapies.
Received for publication, January 3, 2006
* This work was supported in part by the Deutsche Forschungsgemeinschaft (DFG, Grant 646/14-1), by the German Competence Network for Viral Hepatitis, and by the Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuernberg (to D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Recipient of Yamanouchi (2002) and Sheila Sherlock (2003) Fellowships of the European Association for the Study of the Liver.
2 Recipient of a scholarship of the DFG graduate college (GRK 750).
3 To whom correspondence should be addressed: Division of Gastroenterology and Hepatology, Beth Israel Deaconess MC, Harvard Medical School, Dana 501, 330 Brookline Ave, Boston, MA 02215. Tel.: 617-667-8377; Fax: 617-667-2767; E-mail: dschuppa{at}bidmc.harvard.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P. Fu, J. A. Thompson, and L. A. Bach Promotion of Cancer Cell Migration: AN INSULIN-LIKE GROWTH FACTOR (IGF)-INDEPENDENT ACTION OF IGF-BINDING PROTEIN-6 J. Biol. Chem., August 3, 2007; 282(31): 22298 - 22306. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Fallowfield, M. Mizuno, T. J. Kendall, C. M. Constandinou, R. C. Benyon, J. S. Duffield, and J. P. Iredale Scar-Associated Macrophages Are a Major Source of Hepatic Matrix Metalloproteinase-13 and Facilitate the Resolution of Murine Hepatic Fibrosis J. Immunol., April 15, 2007; 178(8): 5288 - 5295. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |